MedPath

SAKAKIBARA HEART INSTITUTE

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

20

Active:0
Completed:13

Trial Phases

3 Phases

Phase 1:2
Phase 4:1
Not Applicable:14

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials

Not Applicable
14 (82.4%)
Phase 1
2 (11.8%)
Phase 4
1 (5.9%)

The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)

Completed
Conditions
Atheroscleroses, Coronary
Atherosclerosis of Artery
Cancers
First Posted Date
2019-12-13
Last Posted Date
2019-12-18
Lead Sponsor
Sakakibara Heart Institute
Target Recruit Count
8856
Registration Number
NCT04198896

Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration

Phase 1
Conditions
Chronic Heart Failure
Old Myocardial Infarction
First Posted Date
2017-11-22
Last Posted Date
2021-03-18
Lead Sponsor
Sakakibara Heart Institute
Target Recruit Count
6
Registration Number
NCT03351400
Locations
🇯🇵

Sakakibara Heart Institute, Tokyo, Japan

Pathogenic Mechanisms of Cancer and Cardiovascular Diseases

Completed
Conditions
Cancer
Pathogenesis
Cardiovascular Diseases
First Posted Date
2017-02-13
Last Posted Date
2020-10-22
Lead Sponsor
Sakakibara Heart Institute
Target Recruit Count
66
Registration Number
NCT03051191
Locations
🇯🇵

Sakakibara Heart Institute, Fuchu, Japan

🇯🇵

The Cancer Institute Hospital for Japanese Foundation for Cancer Research, Tokyo, Japan

The Sakakibara Health Integrative Profile Cohort Study

Completed
Conditions
Cancer
First Posted Date
2016-12-29
Last Posted Date
2016-12-30
Lead Sponsor
Sakakibara Heart Institute
Target Recruit Count
32095
Registration Number
NCT03005834

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.